All In Biotech

Drug Trial Radar · NCT05132582

A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)

Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 654 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

654

Actual

Start

Mar 7, 2022

Primary completion

Sep 5, 2025

Study completion Sep 28, 2027

Sponsor

Sponsor type
Industry
First posted
Nov 24, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being done to see if tucatinib works better than placebo when given with other drugs to treat participants with HER2-positive breast cancer. A placebo is a pill that looks the same as tucatinib but has no medicine in it. This study will also test what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease. Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic). In this study, all participants will get either tucatinib or placebo. Participants will be assigned randomly to a group. This is a blinded study, so patients and their doctors will not know which group a participant is in. All participants will also get trastuzumab and pertuzumab. These are 2 drugs used to treat this type of cancer.

Conditions

  • HER2 Positive Breast Cancer

Interventions

  • TucatinibDrug

    300mg given by mouth (orally) twice daily

  • TrastuzumabDrug

    6mg/kg given into the vein (IV; intravenously) or 600mg injected under the skin (SC; subcutaneous) every 21 days

  • PertuzumabDrug

    420mg given by IV every 21 days

  • Combination product: Trastuzumab + PertuzumabDrug

    600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase will be given by subcutaneous injection every 21 days. May be given in place of trastuzumab and pertuzumab individually.

  • PlaceboDrug

    Given orally twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) as Assessed by Investigator Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1Time frame: From randomization until the first documentation of PD or death from any cause or censoring date, whichever occurred first (maximum treatment exposure was of 41.3 months)

Locations

307 sites in 23 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Hospital

    Phoenix, Arizona

  • Mayo Clinic

    Scottsdale, Arizona

  • Central Arkansas Radiation Therapy Institute Inc d.b.a CARTI

    Little Rock, Arkansas

  • UCLA Hematology/Oncology - Beverly Hills

    Beverly Hills, California

  • UCLA Hematology/Oncology - Burbank

    Burbank, California

  • UCSD Medical Center - Encinitas

    Encinitas, California

  • Sulpizio Cardiovascular Center at UC San Diego Health

    La Jolla, California

  • UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion)

    La Jolla, California

  • UCSD Koman Family Outpatient Pavilion

    La Jolla, California

  • UCSD Perlman Medical Offices

    La Jolla, California

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • UCLA Hematology/Oncology - Laguna Hills

    Laguna Hills, California

  • Administrative Address: UCLA Hematology/Oncology

    Los Angeles, California

  • UCLA Hematology/Oncology

    Los Angeles, California

  • UCSD Medical Center - Bankers Hill

    San Diego, California

  • UC San Diego Medical Center - Hillcrest

    San Diego, California

  • UCLA Hematology/Oncology - San Luis Obispo

    San Luis Obispo, California

  • UCLA Hematology/Oncology- Santa Barbara

    Santa Barbara, California

  • UCLA Hematology/Oncology - Santa Monica

    Santa Monica, California

  • UCLA Hematology/Oncology Parkside

    Santa Monica, California

  • Clinical And Translational Research Center

    Torrance, California

  • The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

    Torrance, California

  • Harbor-UCLA Medical Center

    Torrance, California

  • UCLA Hematology/Oncology - Santa Clarita

    Valencia, California

  • UCSD Medical Center - Vista

    Vista, California

  • UCLA Hematology/Oncology- Westlake

    Westlake Village, California

  • AdventHealth Altamonte Infusion Center

    Altamonte Springs, Florida

  • AdventHealth Medical Group Altamonte(second location)

    Altamonte Springs, Florida

  • AdventHealth Medical Group Altamonte

    Altamonte Springs, Florida

  • Mayo Clinic Florida

    Jacksonville, Florida

  • AdventHealth Medical Group Orlando

    Orlando, Florida

  • AdventHealth Orlando Infusion Center

    Orlando, Florida

  • Emory University Hospital Midtown

    Atlanta, Georgia

  • Emory University Clinic

    Atlanta, Georgia

  • Winship Cancer Institute

    Atlanta, Georgia

  • Emory Saint Joseph's Hospital

    Atlanta, Georgia

  • University of Illinois Hospital and Health Systems (Investigational Drug Pharmacy)

    Chicago, Illinois

  • University of Illinois Hospital and Health Systems (Outpatient Cancer Center)

    Chicago, Illinois

  • University of Illinois Hospital and Health Systems

    Chicago, Illinois

  • Norton Cancer Institute - Downtown

    Louisville, Kentucky

Showing 40 of 307 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.